Chloroquine has demonstrated anti-tumor activities through autophagy inhibition and cell cycle disruption. This study aimed to assess the effect of single-agent chloroquine on breast tumor cellular proliferation in a randomized, phase II, double-blind, placebo-controlled, pre-surgical window of opportunity trial.
Patients with newly diagnosed breast cancer were randomized 2:1 to chloroquine 500 mg daily or placebo for 2- to 6-weeks prior to their breast surgery. The primary outcome was the relative change in measures of proliferation (Ki67) in primary breast cancer cells pre- and post-treatment. Adverse events and toxicity profiles were also evaluated.
From September 2015 to December 2016, 70 patients were randomized [46 (66%) chloroquine and 24 (34%) placebo]. Ten patients who were randomized to chloroquine withdrew from study due to adverse events. Mean duration of drug intake was 15 days (range 14–29 days). There were no significant differences between the chloroquine or placebo arms with respect to either the percentage change (− 0.4 vs. − 1.2, p = 0.088) or absolute change (− 2.0% vs. − 5.2%, p = 0.066) in Ki67 index pre- and post-drug treatment. Although adverse effects were minimal and all classified as grade 1, the effects were significant enough to cause nearly 15% of patients to discontinue therapy.
Treatment with single-agent chloroquine 500 mg daily in the preoperative setting was not associated with any significant effects on breast cancer cellular proliferation. It was, however, associated with toxicity that may affect its broader use in oncology.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Levy JMM, Towers CG, Thorburn A (2017) Targeting autophagy in cancer. Nat Rev Cancer 17:528–542. https://doi.org/10.1038/nrc.2017.53
Zheng K, He Z, Kitazato K, Wang Y (2019) Selective autophagy regulates cell cycle in cancer therapy. Theranostics 9:104–125. https://doi.org/10.7150/thno.30308
Chude CI, Amaravadi RK (2017) Targeting autophagy in cancer: update on clinical trials and novel inhibitors. Int J Mol Sci 18(6):1279. https://doi.org/10.3390/ijms18061279
Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A (2019) Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. OncoTargets Ther 12:319–339. https://doi.org/10.2147/OTT.S182685
Zhang Y, Liao Z, Zhang L, Xiao H (2015) The utility of chloroquine in cancer therapy. Curr Med Res Opin 31:1009–1013. https://doi.org/10.1185/03007995.2015.1025731
Xu R, Ji Z, Xu C, Zhu J (2018) The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers. Medicine 97:e12912. https://doi.org/10.1097/MD.0000000000012912
Shi T-T, Yu X-X, Yan L-J, Xiao H-T (2017) Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother Pharmacol 79:287–294. https://doi.org/10.1007/s00280-016-3197-1
Mauthe M, Orhon I, Rocchi C et al (2018) Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14:1435–1455. https://doi.org/10.1080/15548627.2018.1474314
Al-Bari MAA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608–1621. https://doi.org/10.1093/jac/dkv018
Kim EL, Wüstenberg R, Rübsam A et al (2010) Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol 12:389–400. https://doi.org/10.1093/neuonc/nop046
Jiang P, Zhao Y, Shi W et al (2008) Cell growth inhibition, G < sub > 2</sub >/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. Cell Physiol Biochem 22:431–440. https://doi.org/10.1159/000185488
Weyerhäuser P, Kantelhardt SR, Kim EL (2018) Re-purposing chloroquine for glioblastoma: potential merits and confounding variables. Front Oncol 8:335. https://doi.org/10.3389/fonc.2018.00335
Rahim R, Strobl JS (2009) Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20:736–745. https://doi.org/10.1097/CAD.0b013e32832f4e50
Zhang Y, Cao Y, Sun X et al (2017) Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis. Int Immunopharmacol 42:100–107. https://doi.org/10.1016/j.intimp.2016.11.027
Cook KL, Warri A, Soto-Pantoja DR et al (2014) Chloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER + breast cancer. Clin Cancer Res 20:3222–3232. https://doi.org/10.1158/1078-0432.CCR-13-3227
Cufí S, Vazquez-Martin A, Oliveras-Ferraros C et al (2013) The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Sci Rep 3:2469. https://doi.org/10.1038/srep02469
Hu C, Solomon VR, Ulibarri G, Lee H (2008) The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 16:7888–7893. https://doi.org/10.1016/j.bmc.2008.07.076
Briceño E, Calderon A, Sotelo J (2007) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 67:388–391. https://doi.org/10.1016/j.surneu.2006.08.080
Sotelo J, Briceño E, López-González MA (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:337–343
Briceño E, Reyes S, Sotelo J (2003) Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 14:e3
Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A et al (2013) Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol 8:209. https://doi.org/10.1186/1748-717X-8-209
Edmiston KH, McAuliffe P (2009) Study of the efficacy of chloroquine in the treatment of ductal carcinoma in situ (The PINC Trial). In: clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT01023477?term=NCT01023477&draw=1&rank=1.Accessed 4 Jun 2019
Chang JC (2011) Chloroquine with taxane chemotherapy for advanced or metastatic breast cancer after anthracycline failure (CAT). In: clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT01446016?term=NCT01446016&rank=1.Accessed 4 Jun 2019
Levasseur N, Clemons M, Hilton J et al (2015) Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer? Minerva Chir 70:181–193
Arnaout A, Robertson S, Kuchuk I et al (2015) Evaluating the feasibility of performing window of opportunity trials in breast cancer. Int J Surg Oncol 2015:785793. https://doi.org/10.1155/2015/785793
Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183. https://doi.org/10.1016/S1470-2045(09)70262-1
Fasching PA, Heusinger K, Haeberle L et al (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486. https://doi.org/10.1186/1471-2407-11-486
Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:907–922. https://doi.org/10.1043/1543-2165-134.6.907
Marmor MF, Kellner U, Lai TYY et al (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:415–422. https://doi.org/10.1016/j.ophtha.2010.11.017
National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) version 4.0
Niraula S, Dowling RJO, Ennis M et al (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821–830. https://doi.org/10.1007/s10549-012-2223-1
Hadad S, Iwamoto T, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783–794. https://doi.org/10.1007/s10549-011-1612-1
Glimelius B, Lahn M (2011) Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol 22:1717–1725. https://doi.org/10.1093/annonc/mdq622
Kalinsky K, Hershman DL (2012) Cracking open window of opportunity trials. J Clin Oncol 30:2573–2575. https://doi.org/10.1200/JCO.2012.42.3293
Sui X, Chen R, Wang Z et al (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e838. https://doi.org/10.1038/cddis.2013.350
World Health Organization Chloroquine. http://archives.who.int/emlib/MedicineDisplay5c98.html. Accessed 17 Jun 2019
Pascolo S (2016) Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol 771:139–144. https://doi.org/10.1016/j.ejphar.2015.12.017
Weniger H, World Health Organization (1979) Review of side effects and toxicity of chloroquine. World Health Organization, Geneva
Schmitz S, Duhoux F, Machiels J-P (2016) Window of opportunity studies: do they fulfil our expectations? Cancer Treat Rev 43:50–57. https://doi.org/10.1016/j.ctrv.2015.12.005
True LD (2008) Quality control in molecular immunohistochemistry. Histochem Cell Biol 130:473–480. https://doi.org/10.1007/s00418-008-0481-0
Polley M-YC, Leung SCY, McShane LM et al (2013) An international Ki67 reproducibility study. JNCI J Natl Cancer Inst 105:1897–1906. https://doi.org/10.1093/jnci/djt306
Pu X, Storr SJ, Zhang Y et al (2017) Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis 22:357–368. https://doi.org/10.1007/s10495-016-1323-5
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28. https://doi.org/10.1136/ard.2008.101766
Schroeder RL, Gerber JP (2014) Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies. Toxicol Rep 1:963–968. https://doi.org/10.1016/j.toxrep.2014.10.019
Costedoat-Chalumeau N, Dunogué B, Leroux G et al (2015) A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol 49:317–326. https://doi.org/10.1007/s12016-015-8469-8
The authors are grateful to the research staff for their assistance in recruiting participants and for data collection.
This trial was supported by the Canadian Breast Cancer Foundation Ontario Chapter and University of Ottawa Department of Surgery research Grant.
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ottawa Hospital Research Ethics Board) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Arnaout, A., Robertson, S.J., Pond, G.R. et al. A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. Breast Cancer Res Treat 178, 327–335 (2019). https://doi.org/10.1007/s10549-019-05381-y
- Window of opportunity clinical trial
- Breast cancer